Millions of people have suffered acute lung injury as a result of the COVID-19 epidemic. COVID-related Acute Respiratory Distress Syndrome (CARDS) develops in certain patients, and they are unable to be weaned off of mechanical ventilation. Others may develop post-COVID fibrosis, which can lead to significant impairment and the requirement for long-term oxygen therapy. Treatment teams frequently inquire about lung transplantation in each of these instances. In fact, lung transplantation has been used effectively in a small number of patients globally for both CARDS and post-COVID fibrosis. After a COVID infection, lung transplantation poses a variety of particular issues that transplant teams must consider. The inability to do comprehensive psychosocial evaluation and pre transplantation education in patients with severe CARDS, as well as substantial deconditioning from critical illness and infectious worries about virus reactivation, are major roadblocks.Our inadequate understanding of the natural course of healing following COVID-19 infection is worrisome for patients with post-COVID fibrosis. Increased understanding of the incidence and degree of recovery following COVID-19 acute lung injury is critical for making informed transplantation decisions. In compared to a patient with a known progressive Fibrosing Interstitial Lung Disease, transplant specialists must balance the risks and advantages of lung transplantation differently in a post-COVID fibrosis patient who is anticipated to remain stable or gradually improve. Lung transplantation is clearly a life-saving therapeutic option for some COVID-19-infected individuals with significant lung damage. In this research, we look at how lung transplant providers from a number of reputable facilities approach CARDS or post-COVID fibrosis lung transplantation.
